Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy (SUPPORT-1)
A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chennai, India, 600 037
- Madras Medical Mission
-
Mumbai, India, 400 016
- Hinduja Hospital
-
Pune, India, 411 030
- Poona Hospital
-
-
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01608
- St. Vincent Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who have stable coronary artery disease undergoing elective PCI.
- Female subjects not of child-bearing potential.
- Absence of ST segment depression >1.0 mm and absence of ST elevation >1.0 mm in any lead on the baseline 12-lead ECG.
- subjects with CK-MB and troponin-T levels lower than the upper limit of normal.
- Subjects free of acute injuries or illnesses.
Exclusion Criteria:
- Subjects with unstable angina (angina at rest, worsening frequency, duration of angina) or other signs of unstable coronary artery disease.
- Subjects who had had an MI within 14 days prior to the PCI procedure.
- Subjects with conditions that contraindicate the PCI (e.g. coagulopathy, valvular disease, PVD).
- Subjects with history of TIA/stroke within 90 days or any intracranial bleed.
- Subjects with creatinine clearance ≥ 1.5 times the upper limit of normal.
- Subjects with an active history of psychiatric disorders that is likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements.
- Subjects with a history of alcohol or drug abuse.
- Subjects with documented history of human immunodeficiency virus (HIV), or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus positive.
- Subjects with uncorrected clinically significant abnormalities of clinical laboratory tests who in the investigators opinion will interfere with the study conduct.
- Subject with chronic diseases considered by the anesthetist unfit for surgery and/or who in the opinion of the investigator will increase the risk of the study or obscure the interpretation of results.
- Subjects who have participated in a clinical study within 1 month or are currently participating in a clinical study of an investigational agent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Vehicle solution for IV administration single dose.
|
|
Experimental: Low dose
|
Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
|
|
Experimental: High Dose
|
Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
|
|
Experimental: Mid Dose
|
Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety as measured by changes in CK-MB
Time Frame: within 24 hours
|
within 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cardiac biomarkers
Time Frame: within 24 hours
|
within 24 hours
|
|
ST segment changes
Time Frame: within 24 hours
|
within 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Alan S. Lader, Ph.D., Ischemix, LLC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CMX-2043-2a
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.